Cancer drug combo trial halted early: what we know
NCT ID NCT04972110
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 30 times
Summary
This study tested a combination of two drugs (RP-3500 and either niraparib or olaparib) in 156 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find safe doses and see if the combo could shrink tumors. The trial was terminated early, so final results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Participating Site # 1001
Houston, Texas, 77030, United States
-
Participating Site # 1008
New York, New York, 10032, United States
-
Participating Site # 1013
Salt Lake City, Utah, 84112, United States
-
Participating Site # 1016
Rochester, Minnesota, 55905, United States
-
Participating Site #1009
Baltimore, Maryland, 21205, United States
-
Participating Site #1012
New Haven, Connecticut, 06511, United States
-
Participating Site #1015
Ann Arbor, Michigan, 48109, United States
-
Participating Site #1017
Jacksonville, Florida, 32224, United States
-
Participating Site #1018
Phoenix, Arizona, 97401, United States
-
Participating Site #1025
San Francisco, California, 94158, United States
-
Participating Site #1026
New York, New York, 10029, United States
-
Participating Site #1028
Aurora, Colorado, 80012, United States
-
Participating Site #1029
Eugene, Oregon, 97401, United States
Conditions
Explore the condition pages connected to this study.